Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Glenmark Pharmaceuticals
Glenmark Pharmaceuticals
Activities:
Manufacturing
Ingredients
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Regulatory
Glenmark receives Czech GMP certificate for Indian facility
Glenmark Pharmaceuticals' Baddi manufacturing unit in the India has fulfilled GMP recommendation in line with the WHO
Pharmaceutical
Horizon signs license agreement with Glenmark for CHO cell line
gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line has been licenced to be incorporated into the biomanufacturing process
Manufacturing
Glenmark chooses Novartis for respiratory products
The Seebri, Onbrize and Ultibro products are indicated for COPD symptoms and will be manufactured by Novartis for Glenmark's Brazilian subsidiary
Logistics
Glenmark Pharmaceuticals awards UK supply chain to Yusen Logistics
Yusen Logistics, the award-winning pharmaceutical global logistics specialist, has been awarded a major contract by India-based pharmaceutical manufacturer Glenmark Pharmaceuticals
Regulatory
Indian pricing authority to address overcharging by pharma companies
NPPA has decided to chase drug majors for defaulting on penalties that have been imposed for overcharging consumers for medicines
Pharmaceutical
Indian pharma firms develop niche portfolios
They aim to take advantage of generic growth in the US over the next two years
Pharmaceutical
Indian generic manufacturers aim to enter the Japanese market
The penetration of generic drugs in Japan is a little more than 30% compared with more 80% in the US market
Subscribe now